Indian Pharma Market’s Growth Stays Far Behind Expectation In February: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Indian Pharma Market growth in last few months remained below our expectations, even though major Covid-19 concerns are behind and marketing activities mostly back on track.
We believe key reasons for growth below par are -
- subdued new prescription that leads to volume decline,
- digital marketing yield going south and
- sustained lower demand of acute-therapy products.
Amongst top therapies, anti-Infective and respiratory which contributed 20% to IPM were the biggest drags in last several months, while cardiac, anti-diabetic and vitamin-mineral-nutrient contributed major part of growth.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.